Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

被引:8
作者
Ishii, Takahiro [1 ,2 ]
Kawazoe, Akihito [1 ]
Sasaki, Akinori [1 ]
Mishima, Saori [1 ]
Kentaro, Sawada [1 ]
Nakamura, Yoshiaki [1 ]
Kotani, Daisuke [1 ]
Kuboki, Yasutoshi [1 ]
Taniguchi, Hiroya [1 ]
Kojima, Takashi [1 ]
Doi, Toshihiko [1 ]
Yoshino, Takayuki [1 ]
Kuwata, Takeshi [3 ]
Ishii, Genichiro [2 ,3 ]
Shitara, Kohei [1 ]
机构
[1] Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Natl Canc Ctr, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
[2] Juntendo Univ, Grad Sch Med, Courses Adv Clin Res Canc, Tokyo, Japan
[3] Hosp East, Natl Canc Ctr, Dept Pathol & Clin Labs, Kashiwa, Chiba, Japan
关键词
clinical and molecular factors; gastric cancer; irinotecan; nivolumab; third-line or later-line treatment; RANDOMIZED PHASE-III; SUPPORTIVE CARE; DOUBLE-BLIND; CHEMOTHERAPY; PLUS; MONOTHERAPY; METASTASIS; PACLITAXEL; PLATINUM; EFFICACY;
D O I
10.1177/1758835920942377
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. Methods: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or irinotecan group, respectively) from May 2016 to April 2019 following two or more previous lines of chemotherapy. Univariate survival analysis was conducted to identify the clinical and molecular factors associated with progression-free survival (PFS). Results: A total of 156 patients (74 treated with nivolumab and 82 treated with irinotecan) were analyzed. The median PFS was 1.9 months in both treatment groups. The median overall survival (OS) was 7.2 and 6.2 months in the nivolumab and irinotecan groups, respectively. Eastern Cooperative Oncology Group performance status of 1 or more, liver metastasis, a large tumor size at baseline, and HER2-positive status were associated with a worse PFS in the nivolumab group compared with the irinotecan group. The nivolumab group showed a significantly longer PFS (median 3.1versus2.0 months) and OS (median 12.9versus7.8 months) than the irinotecan group in patients with 0 or 1 of these factors, whereas the irinotecan group showed a significantly longer PFS (median 1.0versus1.8 months) and a trend of longer OS (median 3.9versus6.1 months) in patients with > 2 of these factors. Conclusions: Some clinical and molecular factors were associated with outcomes following nivolumab or irinotecan as the third- or later-line treatment in patients with AGC. These factors must be considered while selecting an optimal treatment option.
引用
收藏
页数:12
相关论文
共 50 条
[41]   Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis [J].
Huang, Miao ;
Li, Jisheng ;
Yu, Xuejun ;
Xu, Qian ;
Zhang, Xue ;
Dai, Xin ;
Li, Song ;
Sheng, Lei ;
Huang, Kai ;
Liu, Lian .
FRONTIERS IN ONCOLOGY, 2021, 11
[42]   Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer [J].
Fujii, Hironori ;
Makiyama, Akitaka ;
Iihara, Hirotoshi ;
Okumura, Naoki ;
Yamamoto, Senri ;
Imai, Takeharu ;
Arakawa, Shinichiro ;
Kobayashi, Ryo ;
Tanaka, Yoshihiro ;
Yoshida, Kazuhiro ;
Suzuki, Akio .
ANTICANCER RESEARCH, 2020, 40 (12) :7067-7075
[43]   Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer [J].
Kato, K. ;
Masuishi, T. ;
Fushiki, K. ;
Nakano, S. ;
Kawamoto, Y. ;
Narita, Y. ;
Tsushima, T. ;
Harada, K. ;
Kadowaki, S. ;
Todaka, A. ;
Yuki, S. ;
Tajika, M. ;
Machida, N. ;
Komatsu, Y. ;
Yasui, H. ;
Muro, K. ;
Kawakami, T. .
ESMO OPEN, 2021, 6 (04)
[44]   Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: A case report [J].
Takahashi, N ;
Suzuki, H ;
Iwabuchi, S ;
Yamazaki, Y ;
Yanaga, K .
HEPATO-GASTROENTEROLOGY, 2005, 52 (61) :326-328
[45]   The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer [J].
Giandomenico Roviello ;
Roberto Petrioli ;
Pietro Rosellini ;
Andrea Giovanni Multari ;
Raffaele Conca ;
Giovanni Paganini ;
Giorgio Chiriacò ;
Michele Aieta .
Investigational New Drugs, 2019, 37 :524-530
[46]   Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis [J].
Rizzo, Alessandro ;
Mollica, Veronica ;
Ricci, Angela Dalia ;
Maggio, Ilaria ;
Massucci, Maria ;
Limpe, Fabiola Lorena Rojas ;
Di Fabio, Francesca ;
Ardizzoni, Andrea .
FUTURE ONCOLOGY, 2020, 16 (02) :4409-4418
[47]   TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer [J].
Spindler, Karen-Lise Garm ;
Christensen, Ib Jarle ;
Nielsen, Hans Jorgen ;
Jakobsen, Anders ;
Bruenner, Nils .
TUMOR BIOLOGY, 2015, 36 (06) :4301-4308
[48]   Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study [J].
Choi, In Sil ;
Choi, Mihong ;
Lee, Ju Hyun ;
Kim, Jee Hyun ;
Suh, Koung Jin ;
Lee, Ji Yun ;
Kang, Beodeul ;
Kim, Ji-Won ;
Kim, Se-Hyun ;
Kim, Jin Won ;
Lee, Jeong-Ok ;
Kim, Yu Jung ;
Bang, Soo-Mee ;
Lee, Jong Seok ;
Lee, Keun-Wook .
PLOS ONE, 2018, 13 (06)
[49]   Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study [J].
Ochenduszko, Sebastian ;
Puskulluoglu, Miroslawa ;
Konopka, Kamil ;
Fijorek, Kamil ;
Slowik, Agnieszka Julia ;
Pedziwiatr, Michal ;
Budzynski, Andrzej .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (04) :223-233
[50]   Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan [J].
Kashiwa, Munenobu ;
Matsushita, Ryo .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2022, 45 (07) :895-903